SCHEMBL4828044

SCHEMBL4828044

CN1C(=O)SC(=Cc2ccc(Oc3ccc(F)cc3)cc2)C1=O

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
HTT P42858 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
IKBKB O14920 7/20 0.54
NPC1 O15118 1/20 0.49
CASP3 P42574 1/20 0.49
RAB9A P51151 1/20 0.49
SENP8 Q96LD8 1/20 0.49
SENP7 Q9BQF6 1/20 0.49
SENP6 Q9GZR1 1/20 0.49
AKR1B1 P15121 1/20 0.49
ENPP2 Q13822 1/20 0.48
MAPK1 P28482 1/20 0.48
KCNH2 Q12809 1/20 0.48
MGAM O43451 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4215334 1.00 KDM4E (0.55) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL17934346 0.91 PIM1 (0.53) TDP1NPC1MGAMCA12CA1
SCHEMBL4566853 0.83 MCL1 (0.57) IKBKBAKR1B1ENPP2
SCHEMBL4869802 0.83 MCL1 (0.57) IKBKBAKR1B1ENPP2
SCHEMBL4207906 0.81 AKR1B1 (0.59) AKR1B1ENPP2MAPK1CA9PIM1
SCHEMBL4207901 0.81 AKR1B1 (0.59) AKR1B1ENPP2MAPK1CA9PIM1
SCHEMBL4209071 0.80 MAPK1 (0.55) IKBKBAKR1B1ENPP2MAPK1PIM1
SCHEMBL4209066 0.80 MAPK1 (0.55) IKBKBAKR1B1ENPP2MAPK1PIM1
SCHEMBL7464201 0.76 CISD1 (0.71) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9
SCHEMBL11321794 0.76 CISD1 (0.71) KDM4ECYP1A2CYP3A4CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7348348-B2 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers MERCK & CO. INC. (US) 2008-03-25 US disclosed
US-20050165072-A1 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers MERCK SHARP & DOHME CORP. 2005-07-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050165072-A1 Aryl-link-aryl substituted thiazolidine-dione and oxazolidine-dione as sodium channel blockers KCNN1, KCNH1, KCNN2 KDM4E 2407/4885CYP1A2 1328/4885CYP3A4 1902/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.